Institutional dossier
The documented history of Isomorphic Labs: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2010 to 2026-10-30 · 0 undated
54 claims · 38 sources · 54 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: Alphabet company announced in 2021; founding and roles are recorded from its own and Alphabet's texts.
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
- Introducing Isomorphic Labs · Archived copy, captured 2021-11-05: Introducing Isomorphic Labs
- Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
- Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson to Combine Industry-Leading AI with World-Class Drug Development in Cross-Modality Strategic Partnership
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2021Record year · 3 claims
- Isomorphic Labs' release of 7 January 2024 states that the company "was founded and is led by" Demis Hassabis.Demis Hassabis → co-founded → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
Participation in founding as the company states; the predicate does not imply sole founding. No founder roster is established, and the release names no other founder.
Founding year as Isomorphic Labs states it: its January 2026 release says the company "was founded in 2021" (recorded separately); the 7 January 2024 release cited here says it "was launched from Alphabet’s DeepMind in 2021" and gives no date of Hassabis's participation. The record is not dated by the release.
- Isomorphic Labs' January 2026 release states that the company "was founded in 2021"; its January 2024 releases state that it was "launched from Alphabet's DeepMind in 2021".Isomorphic Labs → is stated to have been founded in → 2021 Inspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A stated founding year. Neither legal incorporation nor a complete founder roster is established; the launch article's date is recorded separately.
Year as stated; no month, day or incorporation date is given in these releases.
- Isomorphic Labs published its launch article, “Introducing Isomorphic Labs”, in November 2021.Isomorphic Labs → published → Introducing Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
Dated at month precision by the original-period capture (maintainer decision of 2026-10-30), which also names Demis Hassabis as founder and chief executive; this admission could not reach the Internet Archive, so the reading is not repeated here. The page as served in 2026 names no author, so statements in the author’s voice are not attributed to a named person in this record. Publication is not evidence of incorporation; the founding year is recorded separately.
Month of the launch article as its original-period capture of 5 November 2021 displays it (“NOVEMBER 2021”), read by the cross-family machine check of 2026-10-30; the page as served in 2026 displays 1 November 2021, a day no contemporaneous expression confirms.
2024Record year · 3 claims
- Isomorphic Labs' January 2024 release names Demis Hassabis as "CEO and founder of Isomorphic Labs".Demis Hassabis → held role at → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A dated role snapshot. The launch article's statement in the author's voice about serving as CEO is not used because the page names no author. The company's team page of 2026-10-30 lists "Sir Demis Hassabis, PhD" as "Founder and CEO" (context). Existing dataset records cover his DeepMind, Google DeepMind and Alphabet roles.
Source-dated snapshot; no start, end or continuing role is inferred.
- Isomorphic Labs announced on 7 January 2024 a strategic research collaboration with Eli Lilly and Company to discover small-molecule therapeutics against multiple targets, stating an upfront cash payment of $45 million and eligibility for up to $1.7 billion in performance-based milestone payments.Isomorphic Labs → announced a partnership with → Eli Lilly and CompanyInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced · Stage: announced · exact USD 45,000,000 · transaction
Qualification and date notes
Announced terms as Isomorphic Labs states them. The milestone figure is an "up to" eligibility, excluded from the upfront and royalties, and is not a payment received; no programme outcome is implied. The release calls this Isomorphic's "first pharmaceutical partnership" (its own words).
Dated by the release.
- Isomorphic Labs announced on 7 January 2024 a strategic research collaboration with Novartis on small-molecule therapeutics against three undisclosed targets, stating an upfront payment of $37.5 million and eligibility for up to $1.2 billion in performance-based milestone payments.Isomorphic Labs → announced a partnership with → NovartisInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced · Stage: announced · exact USD 37,500,000 · transaction
Qualification and date notes
Announced terms as Isomorphic Labs states them; the milestone figure is an "up to" eligibility, not a payment. The release also states Novartis funding of select research costs, unquantified. No research outcome is implied.
Dated by the release.
2025Record year · 6 claims
- Isomorphic Labs' partnerships page (as served on 2026-10-30) states that Isomorphic and Novartis announced an expansion of their partnership in February 2025, adding up to three research programmes to the initial three targets.Isomorphic Labs → announced a partnership with → NovartisInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Rests on the company's later page, not on the February 2025 announcement; no terms of the expansion are stated there. "Up to three" programmes is the stated bound.
Month as stated by the later page; the February 2025 announcement itself was not retrieved.
- Isomorphic Labs' 31 March 2025 release names Alphabet, an existing investor, as providing follow-on capital in its $600 million round.Alphabet → participated in funding for → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced
Qualification and date notes
Named participation as announced; the round total is not attributed to this investor and no individual amount is stated.
Dated by the release.
- Isomorphic Labs' 31 March 2025 release names GV as a participant in its $600 million round.GV → participated in funding for → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced
Qualification and date notes
Named participation as announced; the round total is not attributed to this investor and no individual amount is stated.
Dated by the release.
- Isomorphic Labs announced on 31 March 2025 that it had raised $600 million in what it calls its "first external funding round".Isomorphic Labs → announced funding of → 600000000 USDInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced · exact USD 600,000,000 · round total
Qualification and date notes
The round total as announced; not a valuation and not any one investor's contribution. Participants are recorded separately without amounts.
Dated by the release.
- Isomorphic Labs' 31 March 2025 release names Thrive Capital as the lead of its $600 million round.Thrive Capital → participated in funding for → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Stage: announced
Qualification and date notes
Named participation as announced; the round total is not attributed to this investor and no individual amount is stated.
Dated by the release.
- Isomorphic Labs announced on 26 November 2025 that Colin Murdoch would step down as President and transition to an advisory role on 1 January 2026.Colin Murdoch → had departure announced from → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
An announced departure from the presidency; the release states that he will remain an adviser, so no end of every association is implied.
The announcement date, not a final working day.
2026Record year · 2 claims
- Isomorphic Labs announced on 20 January 2026 a cross-modality, multi-target research collaboration with Johnson & Johnson (legal entity given as Janssen Biotech, Inc.), under which, as it states, Isomorphic is responsible for in silico predictions and design and Johnson & Johnson for experimental assays and advancing programmes.Isomorphic Labs → announced a partnership with → Johnson & JohnsonInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Announced collaboration as Isomorphic Labs states it; no financial terms are stated in the release and none are inferred.
Dated by the release.
- Isomorphic Labs' team page as served on 2026-10-30 lists Max Jaderberg as President.Max Jaderberg → held role at → Isomorphic LabsInspect claim & evidence ↗
Record about this institution · Stated in source · Supported
Qualification and date notes
A snapshot of the stated title; no tenure is reconstructed.
Undated page; snapshot at retrieval. The appointment was announced on 2025-11-26 as effective 1 January 2026.